Reducing treatment toxicities in the management of good prognosis testicular germ cell tumors

References

• Giwercman A, Carlsen E, Keiding N, Skakkebaek NE. Evidence for increasing incidence of abnormalities of the human testis: a review. Environ. Health Perspect.101(Suppl. 2), 65–71 (1993).
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, dos Santos Silva I, Reid A et al. Trends in cancer incidence and mortality in Scotland: description and possible explanations. Br. J. Cancer77(Suppl. 3), 1–54 (1998).
   PubMedGoogle Scholar
• Einhorn LH. Treatment of testicular cancer: a new and improved model. J. Clin. Oncol.8, 1777–1781 (1990).
   PubMed Web of Science ®Google Scholar
• Nur U, Rachet B, Mitry E et al. Survival from testicular cancer in England and Wales up to 2001. Br. J. Cancer99(Suppl. 1), S80–S82 (2008).
   Google Scholar
• Huddart R, Stahel R, Reinhart C. ESMO minimum clinical recommendations for diagnosis treatment and follow-up of mixed non seminomatous germ cell tumours (NG). Ann. Oncol.16(Suppl. 1), I37–I39 (2005).
   Google Scholar
• Stoter G, Sleyfer DT, ten Bokkel Huinink WW et al. High-dose versus low-dose vinblastine in cisplatin–vinblastine–bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J. Clin. Oncol.4, 1199–1206 (1986).
   PubMed Web of Science ®Google Scholar
• Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol.21, 1513–1523 (2003).
   PubMed Web of Science ®Google Scholar
• Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol.18, 1725–1732 (2000).
   PubMed Web of Science ®Google Scholar
• van den Belt-Dusebout AW, Nuver J, de Wit R et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol.24, 467–475 (2006).
   PubMed Web of Science ®Google Scholar
• Nuver J, Smit AJ, van der Meer J et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J. Clin. Oncol.23, 9130–9137 (2005).
   PubMed Web of Science ®Google Scholar
• Fossa SD. Long-term sequelae after cancer therapy – survivorship after treatment for testicular cancer. Acta Oncol.43, 134–141 (2004).
   PubMed Web of Science ®Google Scholar
• Travis LB, Fossa SD, Schonfeld SJ et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl Cancer Inst.97, 1354–1365 (2005).
   PubMed Web of Science ®Google Scholar
• Leone G, Mele L, Pulsoni A et al. The incidence of secondary leukemias. Haematologica84, 937–945 (1999).
   PubMed Web of Science ®Google Scholar
• Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet367, 754–765 (2006).
   PubMed Web of Science ®Google Scholar
• Huddart RA. Survival from testicular cancer in England and Wales up to 2001. Br. J. Cancer99(Suppl. 1), S83–S85 (2008).
   PubMed Web of Science ®Google Scholar
• Bhardwa JM, Powles T, Berney D et al. Assessing the size and stage of testicular germ cell tumours: 1984–2003. BJU Int.96, 819–821 (2005).
   PubMed Web of Science ®Google Scholar
• Lackner JE, Koller A, Mazal PR et al. The changing distribution of pT stage in testicular germ cell tumours from 1976 to 2005: a single-centre analysis of histopathological reports. BJU Int.98, 747–750 (2006).
   PubMed Web of Science ®Google Scholar
• Sonneveld DJ, Hoekstra HJ, Van Der Graaf WT et al. The changing distribution of stage in nonseminomatous testicular germ cell tumours, from 1977 to 1996. BJU Int.84, 68–74 (1999).
   PubMed Web of Science ®Google Scholar
• de Wit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J. Clin. Oncol.24, 5482–5492 (2006).
   PubMed Web of Science ®Google Scholar
• Albers P, Siener R, Krege S et al. Randomized Phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J. Clin. Oncol.26, 2966–2972 (2008).
   PubMed Web of Science ®Google Scholar
• Albers P, Siener R, Kliesch S et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J. Clin. Oncol.21, 1505–1512 (2003).
   PubMed Web of Science ®Google Scholar
• Donohue JP, Thornhill JA, Foster RS et al. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965–1989. Br. J. Urol.71, 326–335 (1993).
   PubMedGoogle Scholar
• Cullen MH, Stenning SP, Parkinson MC et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J. Clin. Oncol.14, 1106–1113 (1996).
   PubMed Web of Science ®Google Scholar
• van As NJ, Gilbert DC, Money-Kyrle J et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br. J. Cancer98, 1894–1902 (2008).
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Mead GM, Stenning SP et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 – the National Cancer Research Institute Testis Cancer Clinical Studies Group. J. Clin. Oncol.25, 1310–1315 (2007).
   PubMed Web of Science ®Google Scholar
• Dalal PU, Sohaib SA, Huddart R. Imaging of testicular germ cell tumours. Cancer Imaging6, 124–134 (2006).
   PubMedGoogle Scholar
• Dearnaley DP, Fossa SD, Kaye SB et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). Br. J. Cancer92, 2107–2113 (2005).
   PubMed Web of Science ®Google Scholar
• Gilbert DC, Norman AR, Nicholl J et al. Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy. BJU Int.98, 67–69 (2006).
   PubMed Web of Science ®Google Scholar
• Westermann DH, Schefer H, Thalmann GN et al. Long-term follow up results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. J. Urol.179, 163–166 (2008).
   PubMed Web of Science ®Google Scholar
• Read G, Stenning SP, Cullen MH et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J. Clin. Oncol.10, 1762–1768 (1992).
   PubMed Web of Science ®Google Scholar
• Vergouwe Y, Steyerberg EW, Eijkemans MJ et al. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J. Clin. Oncol.21, 4092–4099 (2003).
   PubMed Web of Science ®Google Scholar
• Cattoretti G, Becker MH, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol.168, 357–363 (1992).
   PubMed Web of Science ®Google Scholar
• Albers P, Bierhoff E, Neu D et al. MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer79, 1710–1716 (1997).
   PubMed Web of Science ®Google Scholar
• Albers P, Orazi A, Ulbright TM et al. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors. Mod. Pathol.8, 492–497 (1995).
   PubMed Web of Science ®Google Scholar
• Albers P, Siener R, Hartmann M et al. Risk factors for relapse in stage I non-seminomatous germ-cell tumors: preliminary results of the German Multicenter Trial. German Testicular Cancer Study Group. Int. J. Cancer83, 828–830 (1999).
   PubMed Web of Science ®Google Scholar
• Leibovitch I, Foster RS, Kopecky KK et al. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J. Clin. Oncol.16, 261–268 (1998).
   PubMed Web of Science ®Google Scholar
• Gilbert D, Chandler I, McIntyre A et al. Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. J. Pathol.217(1), 94–102 (2009).
   PubMed Web of Science ®Google Scholar
• Huddart RA, O’Doherty MJ, Padhani A et al.18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22 – the NCRI Testis Tumour Clinical Study Group. J. Clin. Oncol.25, 3090–3095 (2007).
   PubMed Web of Science ®Google Scholar
• Oliver RT, Mason MD, Mead GM et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet366, 293–300 (2005).
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Martin JM, Fossa SD. Late relapses of germ cell malignancies: incidence, management, and prognosis. J. Clin. Oncol.24, 5503–5511 (2006).
   PubMed Web of Science ®Google Scholar
• Warde P, Specht L, Horwich A et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J. Clin. Oncol.20, 4448–4452 (2002).
   PubMed Web of Science ®Google Scholar
• Choo R, Thomas G, Woo T et al. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int. J. Radiat. Oncol. Biol. Phys.61, 736–740 (2005).
   PubMed Web of Science ®Google Scholar
• Chung P, Parker C, Panzarella T et al. Surveillance in stage I testicular seminoma – risk of late relapse. Can.J. Urol.9, 1637–1640 (2002).
   PubMedGoogle Scholar
• Dieckmann KP, Albers P, Classen J et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J. Urol.173, 824–829 (2005).
   PubMed Web of Science ®Google Scholar
• Sohaib SA, Koh DM, Husband JE. The role of imaging in the diagnosis, staging, and management of testicular cancer. AJR Am. J. Roentgenol.191, 387–395.
   PubMed Web of Science ®Google Scholar
• Sohaib SA, Koh DM, Barbachano Y, Parikh J, Husband J, Huddart R. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin. Radiol. (In press) (2008).
   Google Scholar
• Fossa SD, Horwich A, Russell JM et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J. Clin. Oncol.17, 1146 (1999).
   PubMed Web of Science ®Google Scholar
• Jones WG, Fossa SD, Mead GM et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J. Clin. Oncol.23, 1200–1208 (2005).
   PubMed Web of Science ®Google Scholar
• Martin JM, Panzarella T, Zwahlen DR et al. Evidence-based guidelines for following stage 1 seminoma. Cancer109, 2248–2256 (2007).
   PubMed Web of Science ®Google Scholar
• Aparicio J, Garcia del Muro X, Maroto P et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann. Oncol.14, 867–872 (2003).
   PubMed Web of Science ®Google Scholar
• Chung PW, Gospodarowicz MK, Panzarella T et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur. Urol.45, 754–759 (2004).
   PubMed Web of Science ®Google Scholar
• Classen J, Schmidberger H, Meisner C et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J. Clin. Oncol.21, 1101–1106 (2003).
   PubMed Web of Science ®Google Scholar
• Schmidberger H, Bamberg M, Meisner C et al. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int.J. Radiat. Oncol. Biol. Phys.39, 321–326 (1997).
   PubMed Web of Science ®Google Scholar
• Zagars GK, Pollack A. Radiotherapy for stage II testicular seminoma. Int. J. Radiat. Oncol. Biol. Phys.51, 643–649 (2001).
   PubMed Web of Science ®Google Scholar
• de Wit R, Roberts JT, Wilkinson PM et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J. Clin. Oncol.19, 1629–1640 (2001).
   PubMed Web of Science ®Google Scholar
• Arranz Arija JA, Garcia del Muro X, Guma J et al. E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience. Ann. Oncol.12, 487–491 (2001).
   PubMed Web of Science ®Google Scholar
• Krege S, Boergermann C, Baschek R et al. Single agent carboplatin for CS IIA/B testicular seminoma. A Phase II study of the German Testicular Cancer Study Group (GTCSG). Ann. Oncol.17, 276–280 (2006).
   PubMed Web of Science ®Google Scholar
• Patterson H, Norman AR, Mitra SS et al. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother. Oncol.59, 5–11 (2001).
   PubMed Web of Science ®Google Scholar
• Gilbert DC, Van As N, Dearnaley D, Horwich A, Huddart R. Early outcomes of treating stage IIA/B seminoma with a single cycle of carboplatin and radiotherapy. Presented at: ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 14–16 February 2008.
   Google Scholar
• Zwahlen DR, Martin JM, Millar JL, Schneider U. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. Int. J. Radiat. Oncol. Biol. Phys.70, 853–858 (2008).
   PubMed Web of Science ®Google Scholar
• de Wit R, Stoter G, Kaye SB et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J. Clin. Oncol.15, 1837–1843 (1997).
   PubMed Web of Science ®Google Scholar
• Boublikova L OR, Shamash J, Fish R, Mason M, Stenning S. Bleomycin in combination chemotherapy of testicular or extragonadal germ cell tumours: a review of published trials. In: Germ Cell Tumours (5th Edition). Harnden PJK, Jones W (Eds). Springer-Verlag. London, UK 244–246 (2002).
   Google Scholar
• Xiao H, Mazumdar M, Bajorin DF et al. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J. Clin. Oncol.15, 2553–2558 (1997).
   PubMed Web of Science ®Google Scholar
• Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991–1995: a review of patients with germ cell tumours. Br. J. Cancer78, 1061–1066 (1998).
   PubMed Web of Science ®Google Scholar
• O’Sullivan JM, Huddart RA, Norman AR et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncol.14, 91–96 (2003).
   PubMed Web of Science ®Google Scholar
• Hansen SW, Groth S, Sorensen PG et al. Enhanced pulmonary toxicity in smokers with germ-cell cancer treated with cis-platinum, vinblastine and bleomycin: a long-term follow-up. Eur. J. Cancer Clin. Oncol.25, 733–736 (1989).
   PubMedGoogle Scholar
• Lehne G, Johansen B, Fossa SD. Long-term follow-up of pulmonary function in patients cured from testicular cancer with combination chemotherapy including bleomycin. Br. J. Cancer68, 555–558 (1993).
   PubMed Web of Science ®Google Scholar
• Horwich A, Sleijfer DT, Fossa SD et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J. Clin. Oncol.15, 1844–1852 (1997).
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J. Clin. Oncol.11(4), 598–606 (1993).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Kohrmann O, Tischler J et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumors. Ann. Oncol.7, 1015–1021 (1996).
   PubMed Web of Science ®Google Scholar
• McIntyre A, Gilbert D, Goddard N et al. Genes, chromosomes and the development of testicular germ cell tumors of adolescents and adults. Genes Chromosomes Cancer247(7), 547–557 (2008).
   Google Scholar
• Robinson D, Moller H, Horwich A. Mortality and incidence of second cancers following treatment for testicular cancer. Br. J. Cancer96, 529–533 (2007).
   PubMed Web of Science ®Google Scholar
• Richiardi L, Scelo G, Boffetta P et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int. J. Cancer120, 623–631 (2007).
   PubMed Web of Science ®Google Scholar
• van den Belt-Dusebout AW, de Wit R, Gietema JA et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol.25, 4370–4378 (2007).
   PubMed Web of Science ®Google Scholar
• Horwich A, Dearnaley DD, Parker C, Huddart R. Treatment burden following surveillance for stage 1 seminoma of the testis. Presented at: ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 14–16 February 2008.
   Google Scholar